TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03542019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental crown
Description: Replacement og missing tooth structure using monolithic zirconia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid ceramic
Description: Restroration of endodontically treated teeth using hybrid ceramic
Study: NCT01293136

Intervention type: PROCEDURE
Intervention: Femoral nerve block
Description: Ropivacaine

Intervention type: DRUG
Intervention: Intravenous opioids
Description: Whatever opioids prescribed
Study: NCT02391324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lokomat (LOK)
Description: Physical therapy provided using a robotic gait training system (Lokomat).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gait focused physical therapy (fPT)
Description: Overground physical therapy focussed on enhancing gait related motor skills

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LOK + fPT
Description: A combination of robotic gait training and gait focussed functional physical therapy.
Study: NCT03762161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
Study: NCT02043184

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Voice Response (IVR) Reminders
Description: Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) Reminders
Description: Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
Study: NCT04623463

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity intervention
Description: Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
Study: NCT03716453

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard protocol
Description: Give narcotic according to vital signs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANI protocol
Description: ANI score 50-70 indicates optimal narcotic effect. ANI score \> 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score \< 50 indicates inadequate narcotic and narcotic should be given.
Study: NCT01762878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
Study: NCT02868424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fRPE cells
Description: fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
Study: NCT04379154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volatile Organic Compounds analysis
Description: Volatile Organic Compounds analysis in exhaled air by electronic noses
Study: NCT03775317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy
Description: The direct, or conventional, laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Macintosh or Miller laryngoscope for direct visualization of the larynx.
Study: NCT03297216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17P
Description: Synthetic progestin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active placebo comparator
Study: NCT04154943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous (IV) infusion every 3 weeks (Q3W)
Study: NCT03213483

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap and subepithelial connective tissue graft
Description: The connective tissue graft is obtained by a single line incision from the palate.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap and deepithelialized free gingival graft
Description: The connective tissue graft is obtained by deepithelialization of a free gingival graft.
Study: NCT03775317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: The video-assisted laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Storz C-MAC S Video Laryngoscope to allow for indirect visualization of the larynx.
Study: NCT04126031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3
Description: Single intravenous infusion of ceftazidime-avibactam over 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Description: Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
Study: NCT04045574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The 1T1T concept versus conventional implant loading protocol
Description: Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
Study: NCT02853981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic scalpel
Description: a method for liver parenchymal transection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kelly clamp crush technique
Description: a method for liver parenchymal transection
Study: NCT01406652

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage bursectomy
Description: Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage bursectomy
Description: Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
Study: NCT02620709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hula intervention
Description: Hula and heart health education
Study: NCT00976248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken orally once a day
Study: NCT03763799

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCR-based microbiological diagnosis strategy
Description: A multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard microbiological diagnosis strategy
Description: Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
Study: NCT01763814

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: A visible or palpable cephalad movement of the patella will confirm needle placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: A visible or palpable cephalad movement of the patella will confirm needle placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: A visible or palpable cephalad movement of the patella will confirm needle placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block non stimulating catheter
Description: A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block stimulating catheter
Description: A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
Study: NCT02917330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and progressive strength training
Description: Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
Study: NCT00115557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice intervention
Description: Performance feedback, academic detailing, practice facilitation, IT support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practice intervention 2
Description: Performance feedback only.
Study: NCT02177136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04298645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycaemic response to high GI carbohydrates consumed at morning versus evening meals.
Description: Controlled nutrition trial on the glycaemic response to morning and evening meals with high glycemic index carbohydrates among students with early and late chronotypes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycaemic response to high GI carbohydrates consumed at morning versus evening meals.
Description: Controlled nutrition trial on the glycaemic response to morning and evening meals with high glycemic index carbohydrates among students with early and late chronotypes.
Study: NCT04132336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium/Caffeine (BAY2880376)
Description: Tablet, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium/Caffeine (BAY2880376)
Description: Tablet, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium/Caffeine (BAY2880376)
Description: Tablet, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium/Caffeine (BAY2880376)
Description: Tablet, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium (Aleve)
Description: Tablet, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Tablet, oral, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, single dose
Study: NCT03792724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab + Nivolumab
Description: Treatment with intratumoral urelumab after which Nivolumab will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab + Nivolumab
Description: Treatment with intratumoral urelumab after which Nivolumab will be given.
Study: NCT01598350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supramalleolar Orthoses (Cascade)
Description: Walk wearing supramalleolar orthoses - three trial
Study: NCT01884311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subgam
Description: Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
Study: NCT03446963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Groups for Health
Description: Group sessions, 5 modules x 1.5 hours (once per week). Modules focus on psychoeducation, mapping existing social networks, examining barriers to engagement in existing networks, goal setting and identifying new groups to join.
Study: NCT03646760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HYCR
Description: This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBCR
Description: This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
Study: NCT03142919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
Study: NCT04856124

Intervention type: DRUG
Intervention: Intranasal esketamine
Description: Subjects with a clinically meaningful response to IV racemic ketamine were switched to IN esketamine
Study: NCT00969631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)
Description: metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD)
Description: Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
Study: NCT01204450

Intervention type: DRUG
Group type: OTHER
Intervention: Temsirolimus
Description: 60-230mg/m2 weekly during each 28 day course, for up to 12 courses

Intervention type: DRUG
Group type: OTHER
Intervention: Valproic Acid
Description: All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
Study: NCT05223296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compare between two procedure for II-IV degree pile excision
Description: LigaSure or diathermy excision of III-IV degree pile?

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compare between two procedure for II-IV degree pile excision
Description: LigaSure or diathermy excision of III-IV degree pile?
Study: NCT02312063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study: NCT00523965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amphotericin B deoxycholate
Description: Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B with Miltefosine
Description: Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or \> 25 kg Miltefosine 50 mg once daily if patient weighs \<25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B and Paromomycin Sulfate
Description: AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miltefosine + Paromomycin sulfate
Description: oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( \> 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
Study: NCT00521417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: short-term dynamic therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: long-term dynamic therapy
Study: NCT01878487

Intervention type: DEVICE
Group type: OTHER
Intervention: Thrombus aspiration (Intravascular Ultrasound catheter (Boston))
Description: There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~1. At baseline~2. After thrombus aspiration with a thrombus extraction catheter~3. After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such.
Study: NCT03606876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT1806 injection
Description: Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT1806 injection
Description: Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1806 injection
Description: Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
Study: NCT02982798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Rosuvastatin
Description: administration of Metformin + Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Rosuvastatin
Description: administration of Metformin + Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310
Description: administration of JLP-1310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310
Description: administration of JLP-1310
Study: NCT04206514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person Centered Care - Post Abortion Support
Description: Post abortion phone based support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person Centered Care - Post Abortion Support
Description: Post abortion phone based support
Study: NCT02546336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Cooled Radiofrequency Hip Denervation
Description: Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
Study: NCT03251963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Enoxaparin
Description: Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Variable Dose Enoxaparin
Description: Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
Study: NCT01157780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza (fish oil)
Description: Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
Study: NCT04573517

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy
Description: Artificial rupture of amniotic membranes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotomy
Description: Artificial rupture of amniotic membranes
Study: NCT03142919

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study: NCT03489044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
Study: NCT04573517

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley balloon
Description: The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley balloon
Description: The Foley balloon is inserted transcervically and inflated to a volume of 60 cc. It may be spontaneously expelled or manually removed if in place for 12 hours.
Study: NCT04136691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation training
Description: Burn patient scenario was performed with the intervention group.
Study: NCT00939107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care